Search results
Showing 6616 to 6630 of 7680 results
Mepilex Border dressings for preventing pressure ulcers (MIB124)
This advice has been updated and replaced by NICE medical technologies guidance 40.
Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)
This advice has been replaced by NICE diagnostics guidance 36.
FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)
This advice has been updated and replaced by NICE medtech innovation briefing 224.
This advice has been updated and replaced by NICE medical technologies guidance 62.
AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)
This advice has been updated and replaced by NICE medical technologies guidance 65.
This advice has been updated and replaced by NICE medical technologies guidance 66.
KardiaMobile for the ambulatory detection of atrial fibrillation (MIB232)
This advice has been updated and replaced by NICE medical technologies guidance 64.
This advice has been updated and replaced by NICE medical technologies guidance 61.
Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection (MIB247)
This advice has been updated and replaced by NICE guideline NG199.
Personal KinetiGraph for remote clinical management of Parkinson's disease (MIB258)
This advice has been updated and replaced by NICE diagnostics guidance 51.
Magtrace and Sentimag for locating sentinel lymph nodes (MIB263)
This advice has been updated and replaced by NICE medical technologies guidance 72.
SeQuent Please balloon catheter for in-stent coronary restenosis (MTG1)
This medical technologies guidance has been replaced by the recommendations in the NICE guideline on acute coronary syndromes.
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.
Vision Amniotic Leak Detector to assess unexplained vaginal wetness in pregnancy (MTG15)
In March 2019, NICE reviewed this guidance and recommended it should be withdrawn because Vision Amniotic Leak Detector is no longer available. NICE has produced a medtech innovation briefing on AmnioSense for unexplained vaginal wetness in pregnancy. For a copy of the review decision, please contact nice@nice.org.uk.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)
This guidance has been updated and replaced by NICE medical technologies guidance 58.